Fredun Pharmaceuticals Ltd
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
- Market Cap ₹ 360 Cr.
- Current Price ₹ 768
- High / Low ₹ 1,249 / 650
- Stock P/E 24.9
- Book Value ₹ 238
- Dividend Yield 0.09 %
- ROCE 18.9 %
- ROE 13.9 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 43.9% CAGR over last 5 years
- Debtor days have improved from 102 to 46.2 days.
- Company's median sales growth is 23.0% of last 10 years
Cons
- Stock is trading at 3.22 times its book value
- Company has a low return on equity of 10.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 15 | 21 | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 222 | 273 | 311 | |
11 | 14 | 20 | 24 | 38 | 53 | 54 | 87 | 104 | 126 | 208 | 244 | 271 | |
Operating Profit | 0 | 1 | 1 | 2 | 4 | 3 | 6 | 10 | 8 | 8 | 14 | 29 | 40 |
OPM % | 3% | 9% | 7% | 7% | 9% | 6% | 10% | 11% | 7% | 6% | 6% | 11% | 13% |
1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | |
Interest | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | 10 | 13 |
Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 |
Profit before tax | -0 | 0 | 0 | 1 | 2 | 2 | 3 | 6 | 2 | 3 | 9 | 18 | 24 |
Tax % | 0% | 80% | 47% | 52% | 42% | 36% | 34% | 28% | 24% | 37% | 26% | 38% | |
-0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 14 | |
EPS in Rs | -1.02 | 0.04 | 1.02 | 1.11 | 4.55 | 6.08 | 5.11 | 11.18 | 4.76 | 5.04 | 14.30 | 23.85 | 31.24 |
Dividend Payout % | 0% | 0% | 0% | 0% | 13% | 10% | 12% | 6% | 14% | 14% | 5% | 3% |
Compounded Sales Growth | |
---|---|
10 Years: | 34% |
5 Years: | 36% |
3 Years: | 34% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | 68% |
5 Years: | 44% |
3 Years: | 79% |
TTM: | 47% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | 21% |
1 Year: | -13% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 11% |
Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 |
Reserves | 0 | 0 | 0 | 0 | 1 | 2 | 19 | 35 | 37 | 39 | 63 | 84 | 107 |
Preference Capital | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |
5 | 5 | 7 | 9 | 16 | 18 | 10 | 19 | 35 | 40 | 53 | 87 | 65 | |
6 | 7 | 8 | 11 | 24 | 33 | 47 | 47 | 65 | 79 | 66 | 83 | 102 | |
Total Liabilities | 13 | 15 | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 279 |
6 | 6 | 7 | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 42 | |
CWIP | 0 | 0 | 0 | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
7 | 9 | 11 | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 236 | |
Total Assets | 13 | 15 | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 279 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | -1 | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | |
0 | -1 | -2 | -3 | -6 | -7 | -8 | -5 | -1 | -1 | -4 | -9 | |
0 | -0 | 2 | 1 | 3 | 3 | -8 | 4 | 14 | -1 | 7 | 25 | |
Net Cash Flow | 0 | 0 | -0 | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 52 | 47 | 59 | 75 | 98 | 131 | 94 | 67 | 126 | 112 | 148 | 46 |
Inventory Days | 156 | 132 | 107 | 102 | 140 | 68 | 170 | 249 | 227 | 242 | 96 | 264 |
Days Payable | 210 | 131 | 152 | 167 | 221 | 224 | 360 | 205 | 208 | 215 | 101 | 104 |
Cash Conversion Cycle | -2 | 49 | 14 | 11 | 17 | -24 | -96 | 110 | 145 | 139 | 144 | 206 |
Working Capital Days | 22 | 22 | 31 | 20 | 16 | 10 | 42 | 99 | 141 | 144 | 144 | 192 |
ROCE % | 9% | 17% | 14% | 14% | 25% | 18% | 16% | 21% | 10% | 10% | 13% | 19% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 15 Apr
- Compliance Certificate For The Period Ended March 31, 2024 15 Apr
- Board Meeting Outcome for Allotment Of 20,000 Equity Shares To Non-Promoter Upon Conversion Of Warrants Into Equity Shares 15 Apr
- Closure of Trading Window 30 Mar
- Board Meeting Outcome for Board Meeting Outcome For Allotment Of 5000 Equity Shares To Non-Promoter Upon Conversion Of Warrants Into Equity Shares 22 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Business Overview:[1]
Company is a subsidiary of Fredun Group. It manufactures pharmaceutical and allopathic formulations viz. tablets, syrups, capsules, and ointments. Product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral and anti-hypertensive. Company also ventured into manufacturing of dietary/herbal supplements, neutraceuticals, diagnostic kits along with Animal Healthcare products through its group companies Fredun Healthcare Pvt. Ltd. & Fredna Entereprises.
Company has 23 therapeutic classes*(including anti-diabetics, anti-retroviral
and anti-hypertensive), with 450** products registered in overseas markets.